Table 8.
Chemotherapy regimen in patients receiving neoadjuvant versus adjuvant chemotherapy. Treatment.
| Treatment | Neoadjuvant N (%) | Adjuvant N (%) | Total | Chi-square (p-value) |
|---|---|---|---|---|
| All | 214 (26.52%) | 593 (73.48%) | 807 | |
| Chemotherapy1 | 0.01 | |||
| Taxane-containing | 136 (95.10%) | 253 (87.24%) | 389 | |
| No taxane | 7 (4.90%) | 37 (12.76%) | 44 | |
| All Treatments | 0.70 | |||
| Chemo | 113 (52.80%) | 310 (52.28%) | 423 | |
| Chemo + Endocrine | 73 (34.11%) | 221 (37.27%) | 294 | |
| Chemo + Trastuzumab | 10 (4.67%) | 21 (3.54%) | 31 | |
| Chemo + Endocrine + Trastuzumab | 18 (8.41%) | 41 (6.91%) | 59 |
1
Detailed chemotherapy information missing from 374 patients: Neoadjuvant N=143; Adjuvant, N=290.